Applied BioCode (6598) — Cash Flow-to-Debt Ratio
Applied BioCode (6598) has a Cash Flow-to-Debt Ratio of -0.06x as of September 2025, meaning its operating cash flow of NT$-19.88 Million could theoretically repay 0% of its total liabilities (NT$343.23 Million) in one year. See Applied BioCode free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Applied BioCode Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for Applied BioCode across 12 annual periods. Also explore 6598 net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Applied BioCode (2013–2024)
Year-by-year debt coverage analysis for Applied BioCode. For market capitalisation and broader financial context, see 6598 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.62x | NT$-207.74 Million | NT$336.07 Million | ▼ -0.1% |
| 2023 | -0.62x | NT$-205.09 Million | NT$332.22 Million | ▼ -267.7% |
| 2022 | 0.37x | NT$145.87 Million | NT$396.38 Million | ▲ +128.1% |
| 2021 | -1.31x | NT$-151.77 Million | NT$116.01 Million | ▼ -25.0% |
| 2020 | -1.05x | NT$-146.74 Million | NT$140.23 Million | ▲ +37.2% |
| 2019 | -1.67x | NT$-313.84 Million | NT$188.36 Million | ▲ +52.7% |
| 2018 | -3.52x | NT$-286.71 Million | NT$81.35 Million | ▲ +15.1% |
| 2017 | -4.15x | NT$-250.36 Million | NT$60.30 Million | ▲ +52.7% |
| 2016 | -8.77x | NT$-448.96 Million | NT$51.17 Million | ▼ -70.6% |
| 2015 | -5.14x | NT$-209.24 Million | NT$40.67 Million | ▼ -55.6% |
| 2014 | -3.31x | NT$-128.80 Million | NT$38.97 Million | ▲ +15.0% |
| 2013 | -3.89x | NT$-91.93 Million | NT$23.63 Million | — |